Pembrolizumab berahyaluronidase alfa vs Sintilimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Pembrolizumab berahyaluronidase alfa · Keytruda Qlex
Marketed by Merck & Co.
NCT05722015 · Phase 3 · active, not recruiting
Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.
Next expected readout: December 2029 · NCT07190248 (registry estimate)
Reported efficacy
Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)
Result source: NCT05722015
Sintilimab
Marketed by Innovent Biologics and partners
NCT03607539 · Phase 3 · completed
This trial was randomized, quadruple-blinded, and placebo-controlled with a reasonably large sample (397 patients) and used a hard clinical primary endpoint (progression-free survival), which is a strong design overall. However, the results record reports only median PFS values and confidence intervals for each arm (8.9 vs 5.0 months) without a p-value or hazard ratio, so whether the primary comparison reached statistical significance cannot be confirmed from the data provided.
Next expected readout: November 2026 · NCT05429463 (registry estimate)
Reported efficacy
Overall Survival (Through database cutoff date of 31-July-2020 (up to approximately 35 months)): Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022). (met)
Result source: NCT03150875
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Pembrolizumab berahyaluronidase alfa | Sintilimab |
|---|---|---|
| PFS, median | —Trial running · NCT05722015 | 8.9 vs 5+3.9 vs placeboNCT036075392 other results
|
| OS, median | —Trial running · NCT05722015 | 11.8 vs 8.3vs DocetaxelNCT03150875 |
| ORR | 64.3% vs 18.2%vs PembrolizumabNCT06212752 | 51.9% vs 29.8%+22.1 vs placeboNCT036075392 other results
|
| Duration of response, median | —Trial running · NCT05722015 | 6.0 vs 5.1+1 vs placeboNCT036299251 other result
|
PFS, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Sintilimab
- 8.9 vs 5+3.9 vs placeboNCT03607539
2 other results
- 5.5 vs 4.9 NCT03629925
- 4.3 vs 2.8 NCT03150875
OS, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Sintilimab
- 11.8 vs 8.3vs DocetaxelNCT03150875
ORR
- Pembrolizumab berahyaluronidase alfa
- 64.3% vs 18.2%vs PembrolizumabNCT06212752
- Sintilimab
- 51.9% vs 29.8%+22.1 vs placeboNCT03607539
2 other results
- 44.7% vs 35.4% NCT03629925
- 25.5% vs 2.2% NCT03150875
Duration of response, median
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Sintilimab
- 6.0 vs 5.1+1 vs placeboNCT03629925
1 other result
- 12.4 vs 4.1 NCT03150875
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Pembrolizumab berahyaluronidase alfa: 2 of 4 rows · Sintilimab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pembrolizumab berahyaluronidase alfa | Sintilimab |
|---|---|---|
| Dropout rate | n/a: no completion milestonea NCT05722015 · Phase 3 · combination show 1 more resultn/a: no completion milestone NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | n/a: no completion milestonea NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more resultsn/a: no completion milestone NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT05722015 · Phase 3 · combination show 1 more result— NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | —a NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more results— NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 — NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | 39%a NCT05722015 · Phase 3 · combination show 1 more result42.9% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | 28.2%a NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more results38.9% NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 50.3% NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | show 1 more resultneutropenia 46.4% anaemia 42.9% constipation 39.3% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 | a anaemia 74.1% (placebo 78.6%) neutrophil count decreased 71.1% (placebo 62.6%) white blood cell count decreased 67.7% (placebo 64.1%) NCT03607539 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 2 more resultsanaemia 33.3% decreased appetite 23.6% pyrexia 21.5% NCT03150875 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 anaemia 93.3% (placebo 90.4%) white blood cell count decreased 88.8% (placebo 86%) neutrophil count decreased 83.2% (placebo 82%) NCT03629925 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Sintilimab
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab berahyaluronidase alfa's landscape · Sintilimab's landscape